| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
The specific molecular targets of Drinidene are not definitively established in the provided literature. However, based on its reported anti-inflammatory and analgesic activities, it is likely to modulate key proteins or enzymes involved in these pathways. Some 2-aminomethyleneindanone derivatives are known to interact with enzymes like kinases or phosphatases, or to modulate ion channels or receptors involved in pain signaling. The compound's application in pain research, as cited in the patent, suggests that its target(s) may be involved in the transmission or perception of pain. Its broad-spectrum activities (anti-inflammatory, anti-cancer, anti-microbial) could also indicate that it has multiple targets or that its primary target is a pathway central to these diverse biological processes. Further research is needed to fully elucidate its mechanism of action and identify its precise molecular targets.
|
|---|---|
| ln Vitro |
Drinidene has demonstrated in vitro biological activity across several areas. It has been found to exhibit anti-inflammatory, anti-cancer, and anti-microbial properties. This indicates that the compound can modulate cellular processes associated with inflammation, inhibit the growth of cancer cells, and exert effects against microorganisms. The specific mechanisms underlying these activities are not detailed in the provided information. However, these findings suggest that Drinidene is a biologically active compound with the potential to affect multiple pathways. Its activity in vitro makes it a compound of interest for further study to understand its mechanism of action and to explore its potential therapeutic applications.
|
| ln Vivo |
Specific in vivo activity data for Drinidene is not detailed in the provided search results. However, its investigation for the research of pain disorders suggests it has been evaluated in animal models of pain. In such models, the compound would be administered to animals (likely rodents) to assess its ability to reduce pain-related behaviors. The results of these studies are not publicly available, but they would be crucial for confirming its in vivo efficacy and for understanding its pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
Specific in vitro enzyme or receptor binding assay protocols for Drinidene are not described in the provided literature. As a research compound, its biological activity would be characterized using standard assays depending on the intended target. For its anti-inflammatory activity, assays might involve measuring its ability to inhibit the production of pro-inflammatory cytokines or the activity of enzymes like COX or LOX. For its anti-cancer activity, cell viability assays on cancer cell lines would be used. For its anti-microbial properties, standard broth microdilution assays to determine minimum inhibitory concentrations (MICs) would be employed.
|
| Cell Assay |
In vitro cell-based assays for Drinidene would be designed based on its reported activities. To study its anti-inflammatory effects, immune cells (such as macrophages) could be stimulated with LPS and treated with Drinidene, and the production of inflammatory cytokines (e.g., TNF-α, IL-6) would be measured by ELISA. For anti-cancer studies, various cancer cell lines would be treated with the compound, and cell viability, proliferation, or apoptosis would be assessed. For antimicrobial studies, the compound would be tested against a panel of bacterial or fungal strains. These assays are standard for characterizing the biological activities of novel compounds.
|
| Animal Protocol |
Specific in vivo animal study protocols for Drinidene are not described in the provided literature. However, based on its use in pain research, a typical study would involve a rodent model of pain, such as the formalin test, the hot plate test, or the von Frey test for neuropathic pain. In these models, animals are treated with Drinidene (likely via oral or intraperitoneal administration), and their response to a painful stimulus is measured. A reduction in pain-related behavior in the treated group compared to the control group would indicate an analgesic effect.
|
| ADME/Pharmacokinetics |
Detailed pharmacokinetic data for Drinidene is not available in the provided literature. As a small molecule with a molecular weight of 159.18, it is likely to have favorable drug-like properties, including potential for good oral absorption and tissue penetration. However, without specific studies, its ADME (Absorption, Distribution, Metabolism, Excretion) profile remains unknown.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Drinidene is not publicly available. As with any research compound, its safety profile would need to be established through extensive in vitro and in vivo toxicology studies before it could be considered for therapeutic use. It is classified as a research tool and is not intended for human use.
|
| References |
[1]. https://pubchem.ncbi.nlm.nih.gov/compound/3037167
|
| Additional Infomation |
Drinidene is a research compound with a broad spectrum of reported biological activities, including anti-inflammatory, anti-cancer, and anti-microbial properties. Its unique 2-aminomethyleneindanone core structure makes it an interesting scaffold for medicinal chemistry. It has been investigated for the research of pain disorders. The compound has not received FDA approval for any indication.
|
| Molecular Formula |
C10H9NO
|
|---|---|
| Molecular Weight |
159.18
|
| Exact Mass |
159.068
|
| Elemental Analysis |
C, 75.45; H, 5.70; N, 8.80; O, 10.05
|
| CAS # |
53394-92-6
|
| PubChem CID |
3037167
|
| Appearance |
Light yellow to yellow solid at room temperature
|
| Density |
1.333g/cm3
|
| Boiling Point |
306.1ºC at 760mmHg
|
| Flash Point |
138.9ºC
|
| Index of Refraction |
1.743
|
| LogP |
1.968
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
12
|
| Complexity |
232
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1C2=CC=CC=C2C(=O)C1=CN
|
| InChi Key |
HJOUSWJOPKLCGA-SOFGYWHQSA-N
|
| InChi Code |
InChI=1S/C10H9NO/c11-6-8-5-7-3-1-2-4-9(7)10(8)12/h1-4,6H,5,11H2/b8-6+
|
| Chemical Name |
(2E)-2-(aminomethylidene)-3H-inden-1-one
|
| Synonyms |
Drinidene; 53394-92-6; 2-(Aminomethylene)-1-indanone; 1H-Inden-1-one, 2-(aminomethylene)-2,3-dihydro-; CP24,877; UNII-G715G2AW6N; CP-24,877; Drinidene
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~628.2 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (15.71 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (15.71 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.2822 mL | 31.4110 mL | 62.8220 mL | |
| 5 mM | 1.2564 mL | 6.2822 mL | 12.5644 mL | |
| 10 mM | 0.6282 mL | 3.1411 mL | 6.2822 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
